BXRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Feb 2024 @ 15:53):

Stats
Today's Volume	310 872
Average Volume	424 847
Market Cap	950 330
EPS	$0 ( 2024-03-07 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.000232
ATR14	$0.00100 (4.59%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-09	Mcandrew Natalie	Buy	0
2023-07-03	Kim Yong Chan	Sell	0	Common Stock
2023-07-03	Kim Yong Chan	Sell	4 520 066	Series X Preferred Stock
2022-12-15	Henwood Geraldine	Buy	1 200	Common Stock
2022-06-15	Ashton William	Buy	39 473	Common Stock

INSIDER POWER
-98.28
Last 86 transactions
Buy: 13 000 393 \| Sell: 13 896 192

Baudax Bio Inc Correlation

10 Most Positive Correlations
RMRM	0.937
VERB	0.928
RLAY	0.925
BNTX	0.922
ZD	0.913
NMTR	0.912
ALIM	0.91
NTGR	0.907
MRNA	0.905
HMST	0.901

10 Most Negative Correlations
RMBS	-0.929
LOPE	-0.927
PTMN	-0.918
SNSR	-0.91
KE	-0.91
GRID	-0.908
HOLX	-0.907
FRSG	-0.906
AHRN	-0.904
TER	-0.903

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Baudax Bio Inc Financials

Annual	2022
Revenue:	$1.27M
Gross Profit:	$-5.74M (-452.32 %)
EPS:	$-177.30

Q3	2023
Revenue:	$0
Gross Profit:	$-43 000.00 (0.00 %)
EPS:	$-0.240

Q2	2023
Revenue:	$30 000.00
Gross Profit:	$-74 000.00 (-246.67 %)
EPS:	$-1.510

Q1	2023
Revenue:	$-14 000.00
Gross Profit:	$-419 000 (2 992.86 %)
EPS:	$4.91

Financial Reports:

No articles found.

Baudax Bio Inc

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.